Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) Shares Shorted: Short Interest Down 58.9% in October

Evaxion A/S – Sponsored ADR (NASDAQ:EVAX – Get Free Report) was the recipient of a significant drop in short interest during the month of October. As of October 30th, there was short interest totaling 27,571 shares, a drop of 58.9% from the October 15th total of 67,048 shares. Approximately 0.5% of the company’s shares are short sold. Based on an average daily volume of 189,130 shares, the days-to-cover ratio is currently 0.1 days.

Hedge Funds Weigh In On Evaxion A/S

A number of hedge funds have recently bought and sold shares of the company. Rathbones Group PLC bought a new stake in Evaxion A/S during the first quarter valued at $170,000. Renaissance Technologies LLC bought a new position in shares of Evaxion A/S in the 1st quarter worth about $146,000. Finally, Annis Gardner Whiting Capital Advisors LLC bought a new position in shares of Evaxion A/S in the 1st quarter worth about $112,000. Institutional investors own 11.04% of the company’s stock.

Evaxion A/S Trading Up 1.1%

Evaxion A/S stock traded up $0.03 during mid-day trading on Monday, hitting $2.77. 27,118 shares of the stock were exchanged, compared to its average volume of 138,993. The company has a quick ratio of 5.06, a current ratio of 5.06 and a debt-to-equity ratio of 0.69. Evaxion A/S has a 12 month low of $2.65 and a 12 month high of $6.92. The firm’s fifty day simple moving average is $3.12 and its two-hundred day simple moving average is $3.42. The stock has a market capitalization of $24.99 million, a price-to-earnings ratio of -2.29 and a beta of 0.60.

Analyst Ratings Changes

EVAX has been the topic of several research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Evaxion A/S in a report on Tuesday, October 6th. Wall Street Zen upgraded shares of Evaxion A/S to a “hold” rating in a report on Saturday. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Evaxion A/S presently has an average rating of “Moderate Buy” and a consensus price target of $11.25.

Get Our Latest Stock Analysis on Evaxion A/S

About Evaxion A/S

(Get Free Report)

Evaxion A/S is a Denmark-based biotechnology company that uses artificial intelligence to discover and develop immunotherapies and vaccines. Its research focuses on treatments for cancer and infectious diseases, with the goal of identifying targets that can prompt the immune system to recognize and attack disease. The company’s pipeline includes personalized cancer immunotherapy candidates, including EVX-01, as well as vaccine programs for cancer and infectious diseases. Evaxion uses proprietary AI platforms to analyze biological data and identify potential targets for these programs.

Featured Stories

Receive News & Ratings for Evaxion A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evaxion A/S and related companies with MarketBeat.com's FREE daily email newsletter.